The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

SPR announces four featured abstracts that will be presented at the upcoming North American Neuromodulation Society (NANS) Annual Meeting in Orlando, January 29 – February 1. All the abstracts contain ...

Already gaining attention for its mental health and weight-loss benefits, lion’s mane (Hericium erinaceus) is now back in the ...

Neuropathy, a debilitating condition affecting millions worldwide, can significantly impair daily life and well-being. Traditional treatments often fall short, offering temporary relief at best while ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025. Results from this trial are anticipated to be ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new evidence rev ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...